Delivering Sensitive, Specific and Reproducible Data
Next generation sequencing has revolutionized the detection of genomic alterations involved in mechanisms of disease. Specifically, in cancer testing NGS has enabled translational researchers the ability to pinpoint, with certainty, the genomic variants that are specific to tissues, indications and disease progression.
Targeted sequencing has unprecedented levels of sensitivity, detecting the presence of the rarest of somatic changes, and often is the key indicator of possible future recurrence.
Pillar Biosciences' innovative SLIMamp™ technology answers the needs of the front line in oncology by delivering sensitive, specific and reproducible data. Whether for solid tumors, hematological malignancies or liquid biopsy, Pillar is innovating to answer the question: Can we find the answer?